Psychopharmacology Bulletin VOL 37 Supplement No. 1
Efficacy and Tolerability of Controlled-Release Paroxetine
By Robert N. Golden, MD
Pharmacokinetics, Drug Interactions, and Tolerability of Paroxetine and Paroxetine CR
By C. Lindsay DeVane, PharmD
Paroxetine Treatment of Mood and Anxiety Disorders in Children and Adolescents
By Karen Dineen Wagner, MD, PhD
Clinical Management of Perinatal Depression: Focus on Paroxetine
By D. Jeffrey Newport, MD, MSCR, MDiv, and Zachary N. Stowe, MD
Paroxetine Treatment of Mood Disorders in Women: Premenstrual Dysphoric Disorder and Hot Flashes
By Kimberly A. Yonkers, MD
Paroxetine Treatment of Depression in Late Life
By Charles F. Reynolds III, MD
Paroxetine Use in Medically Ill Patients
By Steven Stout, MD, PhD, Wendy I. Somerset, MD, Andrew Miller, MD, and Dominique L. Musselman, MD, MS
Advances in Recognition and Treatment of Social Anxiety Disorder: A 10-Year Retrospective
By Murray B. Stein, MD, FRCPC
Obsessive-Compulsive Disorder: Implications of the Efficacy of an SSRI, Paroxetine
By Philip T. Ninan, MD
Treatment of Posttraumatic Stress Disorder: The Impact of Paroxetine
By Jonathan R.T. Davidson, MD
Paroxetine Treatment of Generalized Anxiety Disorder
By David V. Sheehan, MD, MBA, and C. Gloria Mao, PharmD
Treatment of Panic Disorder: Focus on Paroxetine
By Mark H. Pollack, MD and Alicia C. Doyle, BA
Paroxetine Treatment of Major Depressive Disorder
By Martin B. Keller, MD
In Vivo Neuroimaging Correlates of the Efficacy of Paroxetine in the Treatment of Mood and Anxiety Disorders
By Clinton Kilts, PhD
Neuropharmacology of Paroxetine
By Michael J. Owens, PhD, and Charles B. Nemeroff, MD, PhD
Advancing the Treatment of Mood and Anxiety Disorders: The First 10 Years’ Experience with Paroxetine
By Charles B. Nemeroff, MD, PhD